Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Fajgenbaum

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Nucleic Acids Research|December 12, 2025
Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposingMarcello DeLuca, Nico Matentzoglu, Elliott Sharp, et al.
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
American Journal of Hematology|January 26, 2016
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman diseaseNoriko Iwaki, David C Fajgenbaum, Christopher S Nabel, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Infectious Diseases and Therapy|May 29, 2020
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic ReviewDavid C Fajgenbaum, Johnson S Khor, Alexander Gorzewski, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Nucleic Acids Research|December 12, 2025
Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposingMarcello DeLuca, Nico Matentzoglu, Elliott Sharp, et al.
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
American Journal of Hematology|January 26, 2016
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman diseaseNoriko Iwaki, David C Fajgenbaum, Christopher S Nabel, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Infectious Diseases and Therapy|May 29, 2020
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic ReviewDavid C Fajgenbaum, Johnson S Khor, Alexander Gorzewski, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Pageof 12